BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lam B, Younossi ZM. Treatment options for nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2010;3:121-37. [PMID: 21180596 DOI: 10.1177/1756283X09359964] [Cited by in Crossref: 70] [Cited by in F6Publishing: 40] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Dhurandhar EJ, Krishnapuram R, Hegde V, Dubuisson O, Tao R, Dong XC, Ye J, Dhurandhar NV. E4orf1 improves lipid and glucose metabolism in hepatocytes: a template to improve steatosis & hyperglycemia. PLoS One. 2012;7:e47813. [PMID: 23110104 DOI: 10.1371/journal.pone.0047813] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
2 Srivastava A, Jong S, Gola A, Gailer R, Morgan S, Sennett K, Tanwar S, Pizzo E, O'Beirne J, Tsochatzis E, Parkes J, Rosenberg W. Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease. BMC Gastroenterol 2019;19:122. [PMID: 31296161 DOI: 10.1186/s12876-019-1039-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 12.5] [Reference Citation Analysis]
3 Zhang QQ, Lu LG. Nonalcoholic Fatty Liver Disease: Dyslipidemia, Risk for Cardiovascular Complications, and Treatment Strategy. J Clin Transl Hepatol 2015;3:78-84. [PMID: 26357637 DOI: 10.14218/JCTH.2014.00037] [Cited by in Crossref: 41] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
4 Song HM, Li X, Liu YY, Lu WP, Cui ZH, Zhou L, Yao D, Zhang HM. Carnosic acid protects mice from high-fat diet-induced NAFLD by regulating MARCKS. Int J Mol Med 2018;42:193-207. [PMID: 29620148 DOI: 10.3892/ijmm.2018.3593] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
5 Li Y, Liu L, Wang B, Wang J, Chen D. Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Biomed Rep. 2013;1:57-64. [PMID: 24648894 DOI: 10.3892/br.2012.18] [Cited by in Crossref: 107] [Cited by in F6Publishing: 109] [Article Influence: 11.9] [Reference Citation Analysis]
6 Moreno MF, de Souza GI, Hachul AC, Dos Santos B, Okuda MH, Neto NI, Boldarine VT, Esposito E, Ribeiro EB, do Nascimento CM, Ganen Ade P, Oyama LM. Coacervate whey protein improves inflammatory milieu in mice fed with high-fat diet. Nutr Metab (Lond) 2014;11:15. [PMID: 24673809 DOI: 10.1186/1743-7075-11-15] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
7 Masroor M, Haque Z. HbA1C as a Biomarker of Non-alcoholic Fatty Liver Disease: Comparison with Anthropometric Parameters. J Clin Transl Hepatol 2021;9:15-21. [PMID: 33604251 DOI: 10.14218/JCTH.2019.00046] [Reference Citation Analysis]
8 Na JH, Park SW, Kang Y, Koh H, Kim S. The clinical significance of serum ferritin in pediatric non-alcoholic Fatty liver disease. Pediatr Gastroenterol Hepatol Nutr 2014;17:248-56. [PMID: 25587525 DOI: 10.5223/pghn.2014.17.4.248] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
9 Cholankeril G, Patel R, Khurana S, Satapathy SK. Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management. World J Hepatol 2017; 9(11): 533-543 [PMID: 28469809 DOI: 10.4254/wjh.v9.i11.533] [Cited by in Crossref: 79] [Cited by in F6Publishing: 75] [Article Influence: 19.8] [Reference Citation Analysis]
10 Guo Y, Li JX, Mao TY, Zhao WH, Liu LJ, Wang YL. Targeting Sirt1 in a rat model of high-fat diet-induced non-alcoholic fatty liver disease: Comparison of Gegen Qinlian decoction and resveratrol. Exp Ther Med. 2017;14:4279-4287. [PMID: 29104641 DOI: 10.3892/etm.2017.5076] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
11 Eilenberger C, Selinger F, Rothbauer M, Lin Y, Limbeck A, Schädl B, Grillari J, Kavok NS, Klochkov VK, Malyukin YV, Margitich V, Ertl P. Cytotoxicity, Retention, and Anti-inflammatory Effects of a CeO2 Nanoparticle-Based Supramolecular Complex in a 3D Liver Cell Culture Model. ACS Pharmacol Transl Sci 2021;4:101-6. [PMID: 33615164 DOI: 10.1021/acsptsci.0c00170] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Freitas RB, Novaes RD, Gonçalves RV, Mendonça BG, Santos EC, Ribeiro AQ, Lima LM, Fietto LG, Peluzio Mdo C, Leite JP. Euterpe edulis Extract but Not Oil Enhances Antioxidant Defenses and Protects against Nonalcoholic Fatty Liver Disease Induced by a High-Fat Diet in Rats. Oxid Med Cell Longev 2016;2016:8173876. [PMID: 27418954 DOI: 10.1155/2016/8173876] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
13 陈韵, 李珏宏, 李昌平, 钟晓琳, 康敏. 姜黄素对NAFLD大鼠Visfatin、锌-α2糖蛋白的影响. 世界华人消化杂志 2015; 23(25): 4005-4014 [DOI: 10.11569/wcjd.v23.i25.4005] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
14 Mencarelli A, Distrutti E, Renga B, D’Amore C, Cipriani S, Palladino G, Donini A, Ricci P, Fiorucci S. Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation. PLoS One. 2011;6:e22978. [PMID: 21829567 DOI: 10.1371/journal.pone.0022978] [Cited by in Crossref: 62] [Cited by in F6Publishing: 60] [Article Influence: 6.2] [Reference Citation Analysis]
15 Nobili V, Sanyal AJ. Treatment of nonalcoholic fatty liver disease in adults and children: a closer look at the arsenal. J Gastroenterol 2012;47:29-36. [PMID: 21983927 DOI: 10.1007/s00535-011-0467-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
16 Balaban YH. A key problem and challenge for hepatology: Obesity-related metabolic liver diseases. World J Hepatol 2011; 3(6): 142-146 [PMID: 21860673 DOI: 10.4254/wjh.v3.i6.142] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
17 陈韵, 李昌平. Visfatin、锌-α2糖蛋白在NAFLD发病机制中的研究进展. 世界华人消化杂志 2015; 23(1): 58-63 [DOI: 10.11569/wcjd.v23.i1.58] [Reference Citation Analysis]
18 Ortuño Sahagún D, Márquez-Aguirre AL, Quintero-Fabián S, López-Roa RI, Rojas-Mayorquín AE. Modulation of PPAR-γ by Nutraceutics as Complementary Treatment for Obesity-Related Disorders and Inflammatory Diseases. PPAR Res 2012;2012:318613. [PMID: 23251142 DOI: 10.1155/2012/318613] [Cited by in Crossref: 24] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
19 Li X, Wang R, Zhou N, Wang X, Liu Q, Bai Y, Bai Y, Liu Z, Yang H, Zou J, Wang H, Shi T. Quercetin improves insulin resistance and hepatic lipid accumulation in vitro in a NAFLD cell model. Biomed Rep 2013;1:71-6. [PMID: 24648896 DOI: 10.3892/br.2012.27] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
20 Salter DM, Wei W, Nahar PP, Marques E, Slitt AL. Perfluorooctanesulfonic Acid (PFOS) Thwarts the Beneficial Effects of Calorie Restriction and Metformin. Toxicol Sci 2021;182:82-95. [PMID: 33844015 DOI: 10.1093/toxsci/kfab043] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Dajani A, AbuHammour A. Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview. Saudi J Gastroenterol. 2016;22:91-105. [PMID: 26997214 DOI: 10.4103/1319-3767.178527] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
22 Papazyan R, Sun Z, Kim YH, Titchenell PM, Hill DA, Lu W, Damle M, Wan M, Zhang Y, Briggs ER, Rabinowitz JD, Lazar MA. Physiological Suppression of Lipotoxic Liver Damage by Complementary Actions of HDAC3 and SCAP/SREBP. Cell Metab 2016;24:863-74. [PMID: 27866836 DOI: 10.1016/j.cmet.2016.10.012] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 8.4] [Reference Citation Analysis]
23 Lee DY, Hong KS, Song MY, Yun SM, Ji SD, Son JG, Kim EH. Hepatoprotective Effects of Steamed and Freeze-Dried Mature Silkworm Larval Powder against Ethanol-Induced Fatty Liver Disease in Rats. Foods 2020;9:E285. [PMID: 32143357 DOI: 10.3390/foods9030285] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Bashiardes S, Shapiro H, Rozin S, Shibolet O, Elinav E. Non-alcoholic fatty liver and the gut microbiota. Mol Metab. 2016;5:782-794. [PMID: 27617201 DOI: 10.1016/j.molmet.2016.06.003] [Cited by in Crossref: 121] [Cited by in F6Publishing: 107] [Article Influence: 24.2] [Reference Citation Analysis]
25 Boyraz M, Pirgon Ö, Dündar B, Çekmez F, Hatipoğlu N. Long-Term Treatment with n-3 Polyunsaturated Fatty Acids as a Monotherapy in Children with Nonalcoholic Fatty Liver Disease. J Clin Res Pediatr Endocrinol 2015;7:121-7. [PMID: 26316434 DOI: 10.4274/jcrpe.1749] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 8.4] [Reference Citation Analysis]
26 Dixon LJ, Barnes M, Tang H, Pritchard MT, Nagy LE. Kupffer cells in the liver. Compr Physiol. 2013;3:785-797. [PMID: 23720329 DOI: 10.1002/cphy.c120026] [Cited by in Crossref: 90] [Cited by in F6Publishing: 169] [Article Influence: 11.3] [Reference Citation Analysis]
27 Yang JP, Shin JH, Seo SH, Kim SG, Lee SH, Shin EH. Effects of Antioxidants in Reducing Accumulation of Fat in Hepatocyte. Int J Mol Sci 2018;19:E2563. [PMID: 30158441 DOI: 10.3390/ijms19092563] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
28 Jadeja R, Devkar RV, Nammi S. Herbal medicines for the treatment of nonalcoholic steatohepatitis: current scenario and future prospects. Evid Based Complement Alternat Med 2014;2014:648308. [PMID: 24987431 DOI: 10.1155/2014/648308] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.9] [Reference Citation Analysis]
29 Estadella D, da Penha Oller do Nascimento CM, Oyama LM, Ribeiro EB, Dâmaso AR, de Piano A. Lipotoxicity: effects of dietary saturated and transfatty acids. Mediators Inflamm 2013;2013:137579. [PMID: 23509418 DOI: 10.1155/2013/137579] [Cited by in Crossref: 88] [Cited by in F6Publishing: 79] [Article Influence: 11.0] [Reference Citation Analysis]
30 Li Y, Liu L, Wang B, Wang J, Chen D. Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Biomed Rep. 2013;1:57-64. [PMID: 24648894 DOI: 10.3892/br.2018.18] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Lv WS, Sun RX, Gao YY, Wen JP, Pan RF, Li L, Wang J, Xian YX, Cao CX, Zheng M. Nonalcoholic fatty liver disease and microvascular complications in type 2 diabetes. World J Gastroenterol 2013; 19(20): 3134-3142 [PMID: 23716995 DOI: 10.3748/wjg.v19.i20.3134] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 37] [Article Influence: 4.3] [Reference Citation Analysis]
32 Marques E, Pfohl M, Auclair A, Jamwal R, Barlock BJ, Sammoura FM, Goedken M, Akhlaghi F, Slitt AL. Perfluorooctanesulfonic acid (PFOS) administration shifts the hepatic proteome and augments dietary outcomes related to hepatic steatosis in mice. Toxicol Appl Pharmacol 2020;408:115250. [PMID: 32979393 DOI: 10.1016/j.taap.2020.115250] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
33 张炜煜, 朴熙绪, 金海燕, 李成浩, 金爱花, 韩红梅. 草苁蓉乙醇提取物对大鼠非酒精性脂肪性肝病的保护作用及机制. 世界华人消化杂志 2012; 20(32): 3087-3094 [DOI: 10.11569/wcjd.v20.i32.3087] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Deng Z, Gao S, An Y, Huang Y, Liu H, Zhu W, Lu W, He M, Xie W, Yu D, Li Y. Effects of earthworm extract on the lipid profile and fatty liver induced by a high-fat diet in guinea pigs. Ann Transl Med 2021;9:292. [PMID: 33708919 DOI: 10.21037/atm-20-5362] [Reference Citation Analysis]
35 Wang YL, Liu LJ, Zhao WH, Li JX. Intervening TNF-α via PPARγ with Gegenqinlian Decoction in Experimental Nonalcoholic Fatty Liver Disease. Evid Based Complement Alternat Med. 2015;2015:715638. [PMID: 26221176 DOI: 10.1155/2015/715638] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
36 Behrouz V, Jazayeri S, Aryaeian N, Zahedi MJ, Hosseini F. Effects of Probiotic and Prebiotic Supplementation on Leptin, Adiponectin, and Glycemic Parameters in Non-alcoholic Fatty Liver Disease: A Randomized Clinical Trial. Middle East J Dig Dis 2017;9:150-7. [PMID: 28894517 DOI: 10.15171/mejdd.2017.66] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
37 Stepanova M, Rafiq N, Makhlouf H, Agrawal R, Kaur I, Younoszai Z, McCullough A, Goodman Z, Younossi ZM. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci. 2013;58:3017-3023. [PMID: 23775317 DOI: 10.1007/s10620-013-2743-5] [Cited by in Crossref: 152] [Cited by in F6Publishing: 144] [Article Influence: 19.0] [Reference Citation Analysis]
38 Guo H, Liu G, Zhong R, Wang Y, Wang D, Xia M. Cyanidin-3-O-β-glucoside regulates fatty acid metabolism via an AMP-activated protein kinase-dependent signaling pathway in human HepG2 cells. Lipids Health Dis 2012;11:10. [PMID: 22243683 DOI: 10.1186/1476-511X-11-10] [Cited by in Crossref: 61] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
39 季玲, 李昌平. ChREBP及其靶基因PNPLA3在非酒精性脂肪性肝病发病中的作用. 世界华人消化杂志 2014; 22(2): 179-183 [DOI: 10.11569/wcjd.v22.i2.179] [Reference Citation Analysis]
40 Lu HF, Lai YH, Huang HC, Lee IJ, Lin LC, Liu HK, Tien HH, Huang C. Ginseng-plus-Bai-Hu-Tang ameliorates diet-induced obesity, hepatic steatosis, and insulin resistance in mice. J Ginseng Res 2020;44:238-46. [PMID: 32148405 DOI: 10.1016/j.jgr.2018.10.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]